LT2172212T - Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus - Google Patents

Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus

Info

Publication number: LT2172212T
Authority: LT; Lithuania
Prior art keywords: tumors; against several; immunotherapy against; including neuronal; novel immunotherapy
Prior art date: 2008-10-01

Application number

LTEP08017921.1T

Other languages

English (en)

Inventor

Oliver Schoor

Norbert Hilf

Toni Weinschenk

Claudia Trautwein

Steffen Walter

Harpreet Singh

Original Assignee

Immatics Biotechnologies Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-01

Filing date

2008-10-13

Publication date

2016-11-10

2008-10-13 Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh

2016-11-10 Publication of LT2172212T publication Critical patent/LT2172212T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/34—Antigenic peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- G01N33/5759—
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Mycology (AREA)
General Engineering & Computer Science (AREA)
Oncology (AREA)
Virology (AREA)
Developmental Biology & Embryology (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Toxicology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Anesthesiology (AREA)

LTEP08017921.1T 2008-10-01 2008-10-13 Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus LT2172212T (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP20080017305 EP2172211B1 (en)	2008-10-01	2008-10-01	Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers

Publications (1)

Publication Number	Publication Date
LT2172212T true LT2172212T (lt)	2016-11-10

Family

ID=40342382

Family Applications (10)

Application Number	Title	Priority Date	Filing Date
LTEP08017921.1T LT2172212T (lt)	2008-10-01	2008-10-13	Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP16179174.4T LT3120868T (lt)	2008-10-01	2009-09-28	Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP16179192.6T LT3120869T (lt)	2008-10-01	2009-09-28	Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP16165070.0T LT3069728T (lt)	2008-10-01	2009-09-28	Nauja imunoterapija prieš keletą auglių, įskaitant neuroninius ir smegenų auglius
LTEP16179169.4T LT3132801T (lt)	2008-10-01	2009-09-28	Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP16179163.7T LT3106175T (lt)	2008-10-01	2009-09-28	Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP16179214.8T LT3124043T (lt)	2008-10-01	2009-09-28	Nauja imunoterapija prieš tam tikrus navikus, įskaitant neuronų ir galvos smegenų navikus
LTEP16179226.2T LT3120870T (lt)	2008-10-01	2009-09-28	Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP16179241.1T LT3111952T (lt)	2008-10-01	2009-09-28	Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP09778749.3T LT2331118T (lt)	2008-10-01	2009-09-28	Su navikais susijusių peptidų ir susijusios preišvėžinės vakcinos, skirtos glioblastomos (gbm) ir kitų vėžinių ligų gydymui, kompozicija

Family Applications After (9)

Application Number	Title	Priority Date	Filing Date
LTEP16179174.4T LT3120868T (lt)	2008-10-01	2009-09-28	Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP16179192.6T LT3120869T (lt)	2008-10-01	2009-09-28	Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP16165070.0T LT3069728T (lt)	2008-10-01	2009-09-28	Nauja imunoterapija prieš keletą auglių, įskaitant neuroninius ir smegenų auglius
LTEP16179169.4T LT3132801T (lt)	2008-10-01	2009-09-28	Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP16179163.7T LT3106175T (lt)	2008-10-01	2009-09-28	Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP16179214.8T LT3124043T (lt)	2008-10-01	2009-09-28	Nauja imunoterapija prieš tam tikrus navikus, įskaitant neuronų ir galvos smegenų navikus
LTEP16179226.2T LT3120870T (lt)	2008-10-01	2009-09-28	Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP16179241.1T LT3111952T (lt)	2008-10-01	2009-09-28	Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP09778749.3T LT2331118T (lt)	2008-10-01	2009-09-28	Su navikais susijusių peptidų ir susijusios preišvėžinės vakcinos, skirtos glioblastomos (gbm) ir kitų vėžinių ligų gydymui, kompozicija

Country Status (24)

Country	Link
US (19)	US8119139B2 (lt)
EP (12)	EP2172211B1 (lt)
JP (10)	JP5753783B2 (lt)
KR (6)	KR102133402B1 (lt)
CN (3)	CN102170900B (lt)
AU (2)	AU2009300088B2 (lt)
BR (2)	BRPI0920791B8 (lt)
CA (9)	CA2936869C (lt)
CY (11)	CY1116302T1 (lt)
DK (12)	DK2172211T3 (lt)
EA (3)	EA023378B1 (lt)
ES (12)	ES2536465T3 (lt)
HR (12)	HRP20160915T1 (lt)
HU (11)	HUE031030T2 (lt)
LT (10)	LT2172212T (lt)
MX (3)	MX2011003539A (lt)
NZ (4)	NZ624533A (lt)
PL (12)	PL2172211T3 (lt)
PT (12)	PT2172211E (lt)
RS (12)	RS53782B1 (lt)
SI (12)	SI2172211T1 (lt)
TR (2)	TR201900809T4 (lt)
UA (3)	UA110599C2 (lt)
WO (2)	WO2010037513A1 (lt)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8435507B2 (en)	2004-08-19	2013-05-07	University Of Maryland	Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer
WO2012079878A2 (en) *	2010-12-14	2012-06-21	Immatics Biotechnologies Gmbh	Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
US7612162B2 (en)	2004-09-21	2009-11-03	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
RS54204B1 (sr) *	2007-07-27	2015-12-31	Immatics Biotechnologies Gmbh	Nova imunoterapija protiv tumora mozga
DK2113253T3 (da) *	2008-04-30	2010-07-19	Immatics Biotechnologies Gmbh	Ny sammensætning af tumorassocierede peptider, der bindes til humant leukocyt-antigen (HLA) klasse I eller II molekyler, til vaccinebrug
SI2119726T2 (en) *	2008-05-14	2018-03-30	Immatics Biotechnologies Gmbh	New and powerful Class II MHC peptides derived from survivin and neurocane
RS53782B1 (sr) *	2008-10-01	2015-06-30	Immatics Biotechnologies Gmbh	Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
TW201124530A (en) *	2009-12-01	2011-07-16	Oncotherapy Science Inc	IMP-3 oligopeptides and vaccines including the same
SE535982C2 (sv) *	2009-12-15	2013-03-19	Theravac Pharmaceuticals Ab	Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
AU2015200751B2 (en) *	2010-03-19	2016-11-10	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004551D0 (en)	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
EP2608799B1 (en)	2010-08-24	2018-12-12	University of Pittsburgh - Of the Commonwealth System of Higher Education	Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
WO2012075490A2 (en) *	2010-12-03	2012-06-07	Duke University	Anti-podoplanin antibodies and methods of use
WO2013052158A2 (en) *	2011-04-26	2013-04-11	William Marsh Rice University	Targeted nanovectors and their use for treatment of brain tumors
WO2013040499A1 (en) *	2011-09-14	2013-03-21	Northwestern University	Nanoconjugates able to cross the blood-brain barrier
GB201120779D0 (en)	2011-12-02	2012-01-11	Immodulon Therapeutics Ltd	Cancer therapy
US10201521B2 (en)	2012-01-20	2019-02-12	Del Mar Pharmaceuticals (Bc) Ltd.	Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem and cancer stem cells including glioblastoma multiforme and medulloblastoma
US10704021B2 (en)	2012-03-15	2020-07-07	Flodesign Sonics, Inc.	Acoustic perfusion devices
CN103372217B (zh) *	2012-04-28	2014-12-10	中国科学院深圳先进技术研究院	聚合物纳米载体制剂及其制备方法和应用
PL3536334T3 (pl)	2012-05-16	2021-12-06	Stemline Therapeutics Inc.	Szczepionki przeciw rakowi ukierunkowane na komórki macierzyste raka
CN112587671A (zh) *	2012-07-18	2021-04-02	博笛生物科技有限公司	癌症的靶向免疫治疗
TWI775117B (zh) *	2013-08-05	2022-08-21	德商伊瑪提克斯生物科技有限公司	新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二）
KR102383710B1 (ko) *	2013-08-05	2022-04-08	이매틱스 바이오테크놀로지스 게엠베하	Nsclc를 포함하는 폐암과 같은 여러 가지 종양에 대한 면역요법
GB201319446D0 (en)	2013-11-04	2013-12-18	Immatics Biotechnologies Gmbh	Personalized immunotherapy against several neuronal and brain tumors
MX2019013161A (es) *	2013-11-04	2020-02-03	Immatics Biotechnologies Gmbh	Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
CN104698059B (zh) *	2013-12-04	2017-07-21	苏州中赢医疗科技有限公司	一种脑胶质瘤肿瘤标志物及其应用
GB201322725D0 (en)	2013-12-20	2014-02-05	Immodulon Therapeutics Ltd	Cancer therapy
CA2935960C (en)	2014-01-08	2023-01-10	Bart Lipkens	Acoustophoresis device with dual acoustophoretic chamber
KR101503341B1 (ko) *	2014-03-12	2015-03-18	국립암센터	자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
RS62733B1 (sr)	2014-04-25	2022-01-31	2Seventy Bio Inc	Mnd promoter himernih antigenskih receptora
JP6817069B2 (ja)	2014-04-25	2021-01-20	ブルーバードバイオ，インコーポレイテッド	養子細胞療法薬を製造するための改善された方法
WO2015182668A1 (ja) *	2014-05-28	2015-12-03	学校法人東京女子医科大学	膠芽腫の予測方法
JP2015227292A (ja) *	2014-05-30	2015-12-17	国立大学法人高知大学	膵がん細胞浸潤転移抑制ワクチン
SG10201810723VA (en)	2014-06-06	2018-12-28	Bluebird Bio Inc	Improved t cell compositions
JP6366379B2 (ja) *	2014-06-20	2018-08-01	キヤノン株式会社	被検体情報取得装置
ES2878449T3 (es)	2014-07-24	2021-11-18	2Seventy Bio Inc	Receptores antigénicos quiméricos de BCMA
WO2016070928A1 (en) *	2014-11-06	2016-05-12	Orphan Synergy Europe - Pharma	Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis
RS62527B1 (sr)	2014-12-12	2021-11-30	2Seventy Bio Inc	Bcma receptori himernog antigena
ES2896919T3 (es) *	2014-12-23	2022-02-28	Immatics Biotechnologies Gmbh	Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (CHC) y otros tipos de cáncer
GB201501017D0 (en) *	2014-12-23	2015-03-04	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201423361D0 (en) *	2014-12-30	2015-02-11	Immatics Biotechnologies Gmbh	Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
MY199500A (en)	2015-03-17	2023-11-01	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201505585D0 (en)	2015-03-31	2015-05-13	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
US11708572B2 (en)	2015-04-29	2023-07-25	Flodesign Sonics, Inc.	Acoustic cell separation techniques and processes
US11377651B2 (en)	2016-10-19	2022-07-05	Flodesign Sonics, Inc.	Cell therapy processes utilizing acoustophoresis
KR20240161207A (ko) *	2015-05-06	2024-11-12	이매틱스 바이오테크놀로지스 게엠베하	결장직장 암종(crc) 및 기타 암에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드와 이의 골격의 조합
GB201507719D0 (en) *	2015-05-06	2015-06-17	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
NL2014935B1 (en)	2015-06-08	2017-02-03	Applied Immune Tech Ltd	T cell receptor like antibodies having fine specificity.
US11305002B2 (en)	2015-06-09	2022-04-19	The Board Of Regents Of The University Of Oklahoma	Compositions and treatments for Haemophilus influenzae
RU2733033C2 (ru)	2015-06-24	2020-09-28	Иммодьюлон Терапьютикс Лимитед	Ингибитор контрольных точек и целые клетки микобактерий для применения в терапии рака
MA42294B1 (fr)	2015-07-01	2020-11-30	Immatics Biotechnologies Gmbh	Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
GB201511546D0 (en)	2015-07-01	2015-08-12	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
IL313594A (en) *	2015-07-06	2024-08-01	Immatics Biotechnologies Gmbh	Innovative peptides and a combination of peptides for use in immunotherapy against esophageal cancer and other types of cancer
GB201512369D0 (en) *	2015-07-15	2015-08-19	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) *	2015-08-05	2015-09-23	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IL292864A (en)	2015-08-28	2022-07-01	Immatics Biotechnologies Gmbh	New peptides and a combination of peptides and supports for use in immunotherapy in certain types of cancer
GB201515321D0 (en) *	2015-08-28	2015-10-14	Immatics Biotechnologies Gmbh	Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
WO2017040885A1 (en)	2015-09-03	2017-03-09	The Board Of Regents Of The University Of Oklahoma	Peptide inhibitors of clostridium difficile tcdb toxin
JP7572700B2 (ja)	2015-10-19	2024-10-24	ユニバーシティオブメリーランドボルチモア	改変ヒト初代血液樹状細胞株を生成するための方法
WO2017099712A1 (en)	2015-12-07	2017-06-15	Bluebird Bio, Inc.	Improved t cell compositions
GB201521746D0 (en) *	2015-12-10	2016-01-27	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
HK1255541A1 (zh) *	2015-12-11	2019-08-23	Immatics Biotechnologies Gmbh	用於多种癌症免疫治疗的新型肽和肽组合物
CA3008641A1 (en)	2015-12-16	2017-06-22	Gritstone Oncology, Inc.	Neoantigen identification, manufacture, and use
US10604759B2 (en)	2016-01-15	2020-03-31	City Of Hope	Targeting glioblastoma stem cells through the TLX-TET3 axis
GB201603568D0 (en) *	2016-03-01	2016-04-13	Immatics Biotechnologies Gmbh	Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en)	2016-03-08	2016-04-20	Immatics Biotechnologies Gmbh	Uterine cancer treatments
CN109620949A (zh) *	2016-03-13	2019-04-16	曹帅	一种用于治疗骨癌的药物组合物
RS63727B1 (sr)	2016-03-16	2022-12-30	Immatics Biotechnologies Gmbh	Transficirane t ćelije i t-ćelijski receptori za upotrebu u imunoterapiji protiv malignih tumora
GB201604490D0 (en) *	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Peptides combination of peptides for use in immunotherapy against cancers
GB201604494D0 (en)	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
KR20220097524A (ko) *	2016-04-06	2022-07-07	이매틱스 바이오테크놀로지스 게엠베하	Aml 및 다른 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합
US11214789B2 (en)	2016-05-03	2022-01-04	Flodesign Sonics, Inc.	Concentration and washing of particles with acoustics
WO2017194170A1 (en) *	2016-05-13	2017-11-16	Biontech Rna Pharmaceuticals Gmbh	Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
KR101881300B1 (ko)	2016-06-30	2018-07-25	영남대학교 산학협력단	아조피라졸 화합물 및 은 촉매 반응을 이용한 이의 신규한 합성방법
ES2950435T3 (es) *	2016-10-03	2023-10-10	Ottawa Hospital Res Inst	Composiciones y métodos para mejorar el crecimiento, la propagación y la eficacia oncolítica e inmunoterapéutica de virus oncolíticos de ARN
CN110022906A (zh)	2016-11-04	2019-07-16	蓝鸟生物公司	抗bcma car t细胞组合物
KR102379955B1 (ko)	2016-12-08	2022-03-29	이매틱스 바이오테크놀로지스 게엠베하	짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de)	2016-12-08	2018-06-14	Immatics Biotechnologies Gmbh	T-Zellrezeptoren mit verbesserter Bindung
CN117024560A (zh)	2016-12-22	2023-11-10	库尔生物制药有限公司	T细胞调节性多聚体多肽及其使用方法
CN112210010B (zh)	2017-01-06	2023-12-05	优特力克斯有限公司	抗-人4-1bb抗体及其应用
GB201702863D0 (en) *	2017-02-22	2017-04-05	Evox Therapeutics Ltd	Improved loading of EVs with therapeutic proteins
US20180248175A1 (en) *	2017-02-28	2018-08-30	Lyten, Inc.	Mixed allotrope particulate carbon films and carbon fiber mats
PE20191842A1 (es)	2017-05-08	2019-12-31	Gritstone Oncology Inc	Vectores de neoantigeno de alfavirus
CN107058596A (zh) *	2017-06-19	2017-08-18	上海市第十人民医院	一种与恶性胶质瘤诊断相关的标志物及其应用
CN107034305A (zh) *	2017-06-19	2017-08-11	上海市第十人民医院	恶性胶质瘤的一种诊断标志物
WO2019075112A1 (en)	2017-10-10	2019-04-18	Gritstone Oncology, Inc.	IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
KR102905054B1 (ko)	2017-11-22	2025-12-29	시애틀 프로젝트 코포레이션	신생항원에 대한 접합 에피토프 제시 감소
CN111344402A (zh) *	2017-12-14	2020-06-26	Ezy生物科技有限公司	受试者特异性肿瘤抑制细胞及其用途
EP3725092A4 (en)	2017-12-14	2021-09-22	FloDesign Sonics, Inc.	DRIVE AND CONTROL UNIT FOR ACOUSTIC CONVERTER
HUE060791T2 (hu) *	2018-04-11	2023-04-28	Enterome S A	Antigén peptidek rák megelõzésére és kezelésére
CN108715832B (zh) *	2018-06-01	2020-11-10	段海峰	一种抑制肿瘤生长的间充质干细胞及制备方法和应用
CA3105381A1 (en)	2018-07-11	2020-01-16	The Brigham And Women's Hospital, Inc.	Methods and compositions for delivery of agents across the blood-brain barrier
WO2020110154A1 (en) *	2018-11-30	2020-06-04	Bharat Biotech International Limited	A chimeric therapeutic vaccine
RU2706554C1 (ru) *	2018-12-13	2019-11-19	Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ	Способ создания противоинфекционной иммунологической защиты к Salmonella typhimurium и Listeria monocytogenes с помощью трансгенеза Т-лимфоцитов
CN109796536B (zh) *	2019-02-22	2021-09-17	上海尚泰生物技术有限公司	一种靶向胶质母细胞瘤多种抗原表位的ctl的制备方法
BR112021018854A2 (pt)	2019-03-29	2021-11-30	Intervet Int Bv	Estabilização de bactérias mollicutes vivas em uma composição líquida
EP4600650A3 (en) *	2019-04-05	2025-11-26	Earli Inc.	Improved methods and compositions for synthetic biomarkers
CN114207675A (zh)	2019-05-28	2022-03-18	佩治人工智能公司	用于数字病理学的用于处理图像以针对所处理的图像制备载片的系统和方法
TW202523847A (zh)	2019-05-30	2025-06-16	美商磨石生物公司	經修飾之腺病毒
CN110579457B (zh) *	2019-09-20	2021-11-02	郑州大学第一附属医院	波形蛋白特异响应性荧光探针及其制备方法和应用
CN112824427B (zh) *	2019-11-18	2022-06-24	杨小骏	一种抑制胶质瘤的短肽及其应用
IL294608A (en) *	2020-01-10	2022-09-01	Brigham & Womens Hospital Inc	Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer
JP7777872B2 (ja) *	2020-02-24	2025-12-01	ザリージェンツオブザユニバーシティオブカリフォルニア	細胞ベースの治療を脳にホーミング、ブロック及び送達するための脳特異的抗原の使用
CN113318225B (zh) *	2020-02-28	2024-01-19	无锡派列博生物医药科技有限公司	肿瘤免疫增强剂及其制法和应用
CN113388006A (zh) *	2020-03-18	2021-09-14	北京鼎成肽源生物技术有限公司	一种乳腺癌靶标抗原、乳腺癌靶标抗原刺激培养的ctl细胞及其应用
IL296947A (en) *	2020-03-31	2022-12-01	Walking Fish Therapeutics	Modified b cells and methods of use thereof
EP4127188A4 (en)	2020-03-31	2024-08-21	Walking Fish Therapeutics	MODIFIED B CELLS AND METHODS OF USE THEREOF
CA3169949A1 (en)	2020-05-12	2021-11-18	Cue Biopharma, Inc.	Multimeric t-cell modulatory polypeptides and methods of use thereof
CN116438308A (zh)	2020-08-06	2023-07-14	磨石生物公司	多表位疫苗盒
KR102711471B1 (ko)	2020-08-14	2024-09-30	서울대학교산학협력단	B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물
CA3190707A1 (en) *	2020-08-28	2022-03-03	Torigen Pharmaceuticals, Inc.	Immune memory enhanced preparations and uses thereof
CN116710115A (zh)	2020-11-20	2023-09-05	思维疗法股份有限公司	用于优化的肽疫苗的组合物和方法
US11421015B2 (en)	2020-12-07	2022-08-23	Think Therapeutics, Inc.	Method of compact peptide vaccines using residue optimization
US11058751B1 (en)	2020-11-20	2021-07-13	Think Therapeutics, Inc.	Compositions for optimized RAS peptide vaccines
US20220319638A1 (en) *	2021-03-09	2022-10-06	Bostongene Corporation	Predicting response to treatments in patients with clear cell renal cell carcinoma
US11464842B1 (en)	2021-04-28	2022-10-11	Think Therapeutics, Inc.	Compositions and method for optimized peptide vaccines using residue optimization
US20250235517A1 (en) *	2022-03-30	2025-07-24	Iogenetics, Llc	Tumor-associated antigens in brain tumors
PL441229A1 (pl) *	2022-05-19	2023-11-20	Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk	Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych
KR102907303B1 (ko)	2024-12-23	2025-12-31	전남대학교산학협력단	다중 분기 잠재 확산 모델 기반 초음파 유도 조직 검사 바늘의 경로 및 위치 실시간 검출 장치, 방법
CN120272531B (zh) *	2025-06-10	2025-08-19	鼐济医药科技(杭州)有限公司	一种基于aav介导免疫微环境的脑胶质瘤动物模型构建方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4440859A (en)	1977-05-27	1984-04-03	The Regents Of The University Of California	Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
DK171727B1 (da)	1978-12-22	1997-04-14	Biogen Inc	Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en)	1980-02-22	1982-08-03	Scripps Clinic & Research Foundation	Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en)	1981-09-25	1987-07-07	Genentech, Inc.	Hybrid human leukocyte interferons
US4766075A (en)	1982-07-14	1988-08-23	Genentech, Inc.	Human tissue plasminogen activator
US4582800A (en)	1982-07-12	1986-04-15	Hoffmann-La Roche Inc.	Novel vectors and method for controlling interferon expression
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4757006A (en)	1983-10-28	1988-07-12	Genetics Institute, Inc.	Human factor VIII:C gene and recombinant methods for production
US4677063A (en)	1985-05-02	1987-06-30	Cetus Corporation	Human tumor necrosis factor
US4810648A (en)	1986-01-08	1989-03-07	Rhone Poulenc Agrochimie	Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en)	1986-06-27	1990-01-30	The Administrators Of The Tulane Educational Fund	Method for synthesizing a peptide containing a non-peptide bond
US5338839A (en) *	1988-04-12	1994-08-16	Massachusetts Institute Of Technology	DNA encoding nestin protein
KR100235089B1 (en)	1992-05-14	1999-12-15	Mitsui Chemicals Inc	Ptp or blister packaging articles and packaging material therefor
GB2267257A (en)	1992-05-14	1993-12-01	Ford Motor Co	A vehicle load compartment liner.
ATE183513T1 (de)	1993-06-03	1999-09-15	Therapeutic Antibodies Inc	Herstellung von antikörperfragmenten
AUPM322393A0 (en)	1993-12-24	1994-01-27	Austin Research Institute, The	Mucin carbohydrate compounds and their use in immunotherapy
JP4767371B2 (ja)	1996-01-17	2011-09-07	インペリアル・イノベイションズ・リミテッド	細胞障害性ｔリンパ球（ｃｔｌ）を用いた免疫療法
US5849589A (en)	1996-03-11	1998-12-15	Duke University	Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
IL120561A0 (en) *	1996-04-24	1997-07-13	Akzo Nobel Nv	Peptides suitable for use in immunosuppressive therapy
EP0942748A4 (en) *	1996-07-22	2004-12-08	Univ Rockefeller	ENV-GLYCOPROTEIN VACCINE FOR PROTECTION AGAINST HTLV-I AND HTLV-II INFECTIONS
WO1998031797A1 (en)	1997-01-15	1998-07-23	Zymogenetics, Inc.	Zppar6, human tailless nuclear hormone receptor (tlx receptor)
WO1998036062A1 (en) *	1997-02-13	1998-08-20	Smithkline Beecham Plc	Neural cell adhesion molecule splicing variants
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6682928B2 (en) *	1997-12-02	2004-01-27	Medarex, Inc.	Cells expressing anti-Fc receptor binding components
US7258860B2 (en) *	1998-03-18	2007-08-21	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
AU3762699A (en) *	1998-04-27	1999-11-16	Pacific Northwest Cancer Foundation	(nr-cam) gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
US6960651B2 (en) *	1999-06-29	2005-11-01	Millennium Pharmaceuticals, Inc.	TANGO 332 polypeptides
AU2001241408A1 (en) *	2000-01-31	2001-08-07	Human Genome Sciences, Inc.	Nucleic acids, proteins, and antibodies
US20030139327A9 (en) *	2000-01-31	2003-07-24	Rosen Craig A.	Nucleic acids, proteins, and antibodies
US20040191260A1 (en)	2003-03-26	2004-09-30	Technion Research & Development Foundation Ltd.	Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP2316950A1 (en)	2000-03-27	2011-05-04	Technion Research and Development Foundation, Ltd.	Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
AU2001279581A1 (en) *	2000-09-06	2002-03-22	Friederike Muller	Medicament comprising a dna sequence, which codes for the rna-binding koc protein, and comprising a koc protein or dna sequence of the koc promoter
AU2002226030A1 (en) *	2000-12-04	2002-06-18	Argonex Pharmaceuticals	Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7919467B2 (en)	2000-12-04	2011-04-05	Immunotope, Inc.	Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2002046767A2 (en) *	2000-12-08	2002-06-13	Oxford Glycosciences (Uk) Ltd.	Diagnosis and treatment of alzheimer's disease
WO2002074237A2 (en) *	2001-03-19	2002-09-26	Corixa Corporation	Compositions and methods for the therapy and diagnosis of kidney cancer
CA2364106A1 (fr) *	2001-11-30	2003-05-30	Christopher Gillberg	Polynucleotide et proteine impliques dans la synaptogenese, variants de ceux-ci, et leurs applications therapeutiques et diagnostiques
US6589642B1 (en)	2001-12-21	2003-07-08	Kloeckner Pentaplast Of America, Inc.	Three part high moisture barrier for packages
US7892559B2 (en) *	2002-01-30	2011-02-22	Survac Aps	Survivin-derived peptides and use thereof
US6992176B2 (en)	2002-02-13	2006-01-31	Technion Research & Development Foundation Ltd.	Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (en)	2002-02-20	2003-08-28	Dyax Corp.	Mhc-peptide complex binding ligands
WO2004015390A2 (en) *	2002-08-09	2004-02-19	Applera Corporation	Lung cancer target proteins and use thereof
JP4721633B2 (ja) *	2002-10-11	2011-07-13	財団法人癌研究会	血小板凝集促進活性を有する物質
WO2004067029A1 (fr) *	2002-12-27	2004-08-12	Shenzhen Tsinghua Yuanxing Bio-Pharm Science & Technology Co., Ltd.	Procede de preparation d'un vaccin et vaccins antitumoraux
AU2004228050A1 (en)	2003-04-04	2004-10-21	Board Of Regents, University Of Texas System	Sapphyrins and uses thereof
US7273980B2 (en)	2004-01-13	2007-09-25	Wardle Scott A	Position and velocity transducer using a phonograph disc and turntable
WO2005071075A1 (ja) *	2004-01-23	2005-08-04	Green Peptide Co., Ltd.	上皮細胞増殖因子受容体（egfr）由来ペプチド
DE102004026135A1 (de) *	2004-05-25	2006-01-05	Immatics Biotechnologies Gmbh	An MHC-Moleküle bindende Tumor-assoziierte Peptide
US20080280317A1 (en) *	2004-08-27	2008-11-13	Northeastern University	Comprehensive Characterization Of Complex Proteins At Trace Levels
DE602004019215D1 (de) *	2004-10-02	2009-03-12	Immatics Biotechnologies Gmbh	Immunogene T-Helfer Epitope von menschlichen Tumorantigenen und deren Verwendung in immunotherapeutischen Methoden
CA2600898C (en) *	2004-12-07	2016-08-23	Toray Industries, Inc.	Novel cancer antigen peptide and the use thereof
KR100809410B1 (ko) *	2005-07-06	2008-03-05	주식회사 브레인가드	줄기세포 분화 유도용 조성물 및 그의 용도
SI1760089T1 (sl) *	2005-09-05	2009-12-31	Immatics Biotechnologies Gmbh	S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
ES2341295T3 (es)	2005-09-05	2010-06-17	Immatics Biotechnologies Gmbh	Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
EP1938104A2 (en)	2005-10-17	2008-07-02	Institute for Systems Biology	Tissue-and serum-derived glycoproteins and methods of their use
US20070248628A1 (en) *	2005-12-06	2007-10-25	Keller Lorraine H	Immunogens in cancer stem cells
WO2007072494A1 (en)	2005-12-23	2007-06-28	Naik Praful Ramchandra	Metallized packaging blister container
US9487574B2 (en) *	2006-09-21	2016-11-08	Vaxil Biotherapeutics Ltd.	Antigen specific multi epitope vaccines
US8129184B2 (en) *	2006-09-26	2012-03-06	Cedars-Sinai Medical Center	Cancer stem cell antigen vaccines and methods
EP2164859A4 (en) *	2007-03-06	2012-06-06	Iterative Therapeutics Inc	METHOD AND COMPOSITIONS WITH POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS
WO2009125394A1 (en) *	2008-04-09	2009-10-15	Technion Research & Development Foundation Ltd.	Anti human immunodeficiency antibodies and uses thereof
KR101184869B1 (ko)	2008-04-24	2012-09-20	이매틱스 바이오테크놀로지스 게엠베하	백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형
DK2113253T3 (da) *	2008-04-30	2010-07-19	Immatics Biotechnologies Gmbh	Ny sammensætning af tumorassocierede peptider, der bindes til humant leukocyt-antigen (HLA) klasse I eller II molekyler, til vaccinebrug
RS53782B1 (sr)	2008-10-01	2015-06-30	Immatics Biotechnologies Gmbh	Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
GB201004551D0 (en)	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201021289D0 (en)	2010-12-15	2011-01-26	Immatics Biotechnologies Gmbh	Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
HUE049074T2 (hu) *	2014-05-28	2020-08-28	Nono Inc	TAT-NR2B9c klorid-sója
SG11201808629UA (en)	2016-04-21	2018-11-29	Immatics Biotechnologies Gmbh	Immunotherapy against melanoma and other cancers
US12221465B2 (en) *	2017-09-06	2025-02-11	California Institute Of Technology	Signaling and antigen-presenting bifunctional receptors (SABR)

2008
- 2008-10-01 RS RS20150094A patent/RS53782B1/sr unknown
- 2008-10-01 PT PT80173057T patent/PT2172211E/pt unknown
- 2008-10-01 EP EP20080017305 patent/EP2172211B1/en active Active
- 2008-10-01 SI SI200831373T patent/SI2172211T1/sl unknown
- 2008-10-01 DK DK08017305T patent/DK2172211T3/en active
- 2008-10-01 ES ES08017305.7T patent/ES2536465T3/es active Active
- 2008-10-01 PL PL08017305T patent/PL2172211T3/pl unknown
- 2008-10-13 RS RS20161019A patent/RS55543B1/sr unknown
- 2008-10-13 DK DK08017921.1T patent/DK2172212T3/da active
- 2008-10-13 HU HUE08017921A patent/HUE031030T2/en unknown
- 2008-10-13 EP EP08017921.1A patent/EP2172212B1/en active Active
- 2008-10-13 SI SI200831695A patent/SI2172212T1/sl unknown
- 2008-10-13 ES ES08017921.1T patent/ES2607460T3/es active Active
- 2008-10-13 PL PL08017921T patent/PL2172212T3/pl unknown
- 2008-10-13 PT PT80179211T patent/PT2172212T/pt unknown
- 2008-10-13 LT LTEP08017921.1T patent/LT2172212T/lt unknown
2009
- 2009-09-28 PT PT16165070T patent/PT3069728T/pt unknown
- 2009-09-28 SI SI200932083T patent/SI3120869T1/sl unknown
- 2009-09-28 WO PCT/EP2009/006979 patent/WO2010037513A1/en not_active Ceased
- 2009-09-28 EA EA201100587A patent/EA023378B1/ru unknown
- 2009-09-28 KR KR1020187021349A patent/KR102133402B1/ko active Active
- 2009-09-28 PL PL16179226T patent/PL3120870T3/pl unknown
- 2009-09-28 RS RS20200692A patent/RS60385B1/sr unknown
- 2009-09-28 ES ES16165070T patent/ES2710608T3/es active Active
- 2009-09-28 RS RS20200512A patent/RS60338B1/sr unknown
- 2009-09-28 SI SI200931902T patent/SI3111952T1/sl unknown
- 2009-09-28 ES ES16179226T patent/ES2802227T3/es active Active
- 2009-09-28 PT PT161791694T patent/PT3132801T/pt unknown
- 2009-09-28 SI SI200931464A patent/SI2341927T1/sl unknown
- 2009-09-28 PT PT161792148T patent/PT3124043T/pt unknown
- 2009-09-28 HU HUE16179174A patent/HUE049366T2/hu unknown
- 2009-09-28 CN CN200980139419.2A patent/CN102170900B/zh active Active
- 2009-09-28 DK DK16165070.0T patent/DK3069728T3/en active
- 2009-09-28 LT LTEP16179174.4T patent/LT3120868T/lt unknown
- 2009-09-28 HU HUE09778750A patent/HUE029360T2/en unknown
- 2009-09-28 JP JP2011529471A patent/JP5753783B2/ja not_active Expired - Fee Related
- 2009-09-28 SI SI200932056T patent/SI3124043T1/sl unknown
- 2009-09-28 WO PCT/EP2009/006980 patent/WO2010037514A2/en not_active Ceased
- 2009-09-28 PL PL16165070T patent/PL3069728T3/pl unknown
- 2009-09-28 CN CN200980139420.5A patent/CN102170901B/zh not_active Expired - Fee Related
- 2009-09-28 EP EP16165070.0A patent/EP3069728B1/en active Active
- 2009-09-28 EP EP16179192.6A patent/EP3120869B1/en active Active
- 2009-09-28 CA CA2936869A patent/CA2936869C/en active Active
- 2009-09-28 PL PL16179241T patent/PL3111952T3/pl unknown
- 2009-09-28 SI SI200931573A patent/SI2331118T1/sl unknown
- 2009-09-28 CA CA2936868A patent/CA2936868C/en active Active
- 2009-09-28 RS RS20181585A patent/RS58229B1/sr unknown
- 2009-09-28 RS RS20200693A patent/RS60386B1/sr unknown
- 2009-09-28 EA EA201100586A patent/EA023013B1/ru unknown
- 2009-09-28 ES ES16179169T patent/ES2770090T3/es active Active
- 2009-09-28 NZ NZ624533A patent/NZ624533A/en not_active IP Right Cessation
- 2009-09-28 EP EP16179169.4A patent/EP3132801B1/en active Active
- 2009-09-28 EP EP16179163.7A patent/EP3106175B1/en active Active
- 2009-09-28 SI SI200932065T patent/SI3120868T1/sl unknown
- 2009-09-28 DK DK16179214.8T patent/DK3124043T3/da active
- 2009-09-28 HU HUE16165070A patent/HUE041446T2/hu unknown
- 2009-09-28 MX MX2011003539A patent/MX2011003539A/es active IP Right Grant
- 2009-09-28 AU AU2009300088A patent/AU2009300088B2/en not_active Ceased
- 2009-09-28 MX MX2012012047A patent/MX338294B/es unknown
- 2009-09-28 CA CA2936887A patent/CA2936887C/en active Active
- 2009-09-28 UA UAA201103611A patent/UA110599C2/uk unknown
- 2009-09-28 SI SI200932063T patent/SI3106175T1/sl unknown
- 2009-09-28 PL PL16179169T patent/PL3132801T3/pl unknown
- 2009-09-28 CA CA2739384A patent/CA2739384C/en not_active Expired - Fee Related
- 2009-09-28 ES ES16179214T patent/ES2788129T3/es active Active
- 2009-09-28 JP JP2011529472A patent/JP5855940B2/ja not_active Expired - Fee Related
- 2009-09-28 PL PL16179163T patent/PL3106175T3/pl unknown
- 2009-09-28 RS RS20190118A patent/RS58443B1/sr unknown
- 2009-09-28 PT PT161792262T patent/PT3120870T/pt unknown
- 2009-09-28 DK DK16179163.7T patent/DK3106175T3/da active
- 2009-09-28 LT LTEP16179192.6T patent/LT3120869T/lt unknown
- 2009-09-28 HU HUE16179163A patent/HUE049367T2/hu unknown
- 2009-09-28 ES ES09778750.1T patent/ES2584245T3/es active Active
- 2009-09-28 CN CN201610831523.XA patent/CN106986919A/zh active Pending
- 2009-09-28 KR KR1020207019579A patent/KR102392070B1/ko not_active Expired - Fee Related
- 2009-09-28 DK DK16179169.4T patent/DK3132801T3/da active
- 2009-09-28 PT PT16179241T patent/PT3111952T/pt unknown
- 2009-09-28 EA EA201401104A patent/EA032437B1/ru unknown
- 2009-09-28 DK DK09778749.3T patent/DK2331118T5/da active
- 2009-09-28 LT LTEP16165070.0T patent/LT3069728T/lt unknown
- 2009-09-28 RS RS20160553A patent/RS55043B1/sr unknown
- 2009-09-28 KR KR1020117010000A patent/KR101687840B1/ko not_active Expired - Fee Related
- 2009-09-28 NZ NZ603016A patent/NZ603016A/en not_active IP Right Cessation
- 2009-09-28 PL PL16179192T patent/PL3120869T3/pl unknown
- 2009-09-28 PL PL09778749T patent/PL2331118T3/pl unknown
- 2009-09-28 ES ES16179192T patent/ES2819244T3/es active Active
- 2009-09-28 EP EP16179174.4A patent/EP3120868B1/en active Active
- 2009-09-28 DK DK16179226.2T patent/DK3120870T3/da active
- 2009-09-28 UA UAA201500916A patent/UA125277C2/uk unknown
- 2009-09-28 DK DK16179241.1T patent/DK3111952T3/en active
- 2009-09-28 PT PT161791744T patent/PT3120868T/pt unknown
- 2009-09-28 PT PT97787501T patent/PT2341927T/pt unknown
- 2009-09-28 EP EP16179214.8A patent/EP3124043B1/en active Active
- 2009-09-28 EP EP16179241.1A patent/EP3111952B1/en active Active
- 2009-09-28 CA CA2936982A patent/CA2936982C/en active Active
- 2009-09-28 SI SI200932034T patent/SI3132801T1/sl unknown
- 2009-09-28 HR HRP20160915TT patent/HRP20160915T1/hr unknown
- 2009-09-28 HU HUE16179169A patent/HUE047365T2/hu unknown
- 2009-09-28 RS RS20200973A patent/RS60656B1/sr unknown
- 2009-09-28 PL PL16179214T patent/PL3124043T3/pl unknown
- 2009-09-28 RS RS20161160A patent/RS55531B1/sr unknown
- 2009-09-28 DK DK09778750.1T patent/DK2341927T3/en active
- 2009-09-28 DK DK16179192.6T patent/DK3120869T3/da active
- 2009-09-28 RS RS20200691A patent/RS60381B1/sr unknown
- 2009-09-28 SI SI200931921T patent/SI3069728T1/sl unknown
- 2009-09-28 BR BRPI0920791A patent/BRPI0920791B8/pt not_active IP Right Cessation
- 2009-09-28 RS RS20200085A patent/RS60006B1/sr unknown
- 2009-09-28 PL PL09778750.1T patent/PL2341927T3/pl unknown
- 2009-09-28 PL PL16179174T patent/PL3120868T3/pl unknown
- 2009-09-28 PT PT161791926T patent/PT3120869T/pt unknown
- 2009-09-28 ES ES16179174T patent/ES2804723T3/es active Active
- 2009-09-28 CA CA2936870A patent/CA2936870C/en active Active
- 2009-09-28 ES ES16179241T patent/ES2708654T3/es active Active
- 2009-09-28 KR KR1020117010003A patent/KR101756488B1/ko not_active Expired - Fee Related
- 2009-09-28 NZ NZ591882A patent/NZ591882A/xx not_active IP Right Cessation
- 2009-09-28 HU HUE09778749A patent/HUE030296T2/en unknown
- 2009-09-28 TR TR2019/00809T patent/TR201900809T4/tr unknown
- 2009-09-28 AU AU2009300087A patent/AU2009300087B2/en not_active Ceased
- 2009-09-28 KR KR1020167022929A patent/KR101883426B1/ko active Active
- 2009-09-28 HU HUE16179192A patent/HUE050428T2/hu unknown
- 2009-09-28 EP EP16179226.2A patent/EP3120870B1/en active Active
- 2009-09-28 HU HUE16179241A patent/HUE042115T2/hu unknown
- 2009-09-28 HR HRP20201025TT patent/HRP20201025T8/hr unknown
- 2009-09-28 ES ES16179163T patent/ES2802226T3/es active Active
- 2009-09-28 TR TR2019/00852T patent/TR201900852T4/tr unknown
- 2009-09-28 SI SI200932064T patent/SI3120870T1/sl unknown
- 2009-09-28 NZ NZ591855A patent/NZ591855A/xx not_active IP Right Cessation
- 2009-09-28 LT LTEP16179169.4T patent/LT3132801T/lt unknown
- 2009-09-28 EP EP09778750.1A patent/EP2341927B1/en active Active
- 2009-09-28 LT LTEP16179163.7T patent/LT3106175T/lt unknown
- 2009-09-28 DK DK16179174.4T patent/DK3120868T3/da active
- 2009-09-28 MX MX2011003540A patent/MX2011003540A/es active IP Right Grant
- 2009-09-28 HU HUE16179226A patent/HUE049364T2/hu unknown
- 2009-09-28 PT PT161791637T patent/PT3106175T/pt unknown
- 2009-09-28 PT PT97787493T patent/PT2331118T/pt unknown
- 2009-09-28 BR BRPI0920759A patent/BRPI0920759A2/pt not_active Application Discontinuation
- 2009-09-28 LT LTEP16179214.8T patent/LT3124043T/lt unknown
- 2009-09-28 KR KR1020227013879A patent/KR20220058655A/ko not_active Ceased
- 2009-09-28 LT LTEP16179226.2T patent/LT3120870T/lt unknown
- 2009-09-28 LT LTEP16179241.1T patent/LT3111952T/lt unknown
- 2009-09-28 EP EP09778749.3A patent/EP2331118B1/en active Active
- 2009-09-28 CA CA2936924A patent/CA2936924C/en active Active
- 2009-09-28 HU HUE16179214A patent/HUE051030T2/hu unknown
- 2009-09-28 CA CA2739387A patent/CA2739387C/en active Active
- 2009-09-28 ES ES09778749.3T patent/ES2612466T3/es active Active
- 2009-09-28 HR HRP20170115TT patent/HRP20170115T1/hr unknown
- 2009-09-28 UA UAA201103612A patent/UA103202C2/ru unknown
- 2009-09-28 CA CA2936920A patent/CA2936920C/en active Active
- 2009-09-28 LT LTEP09778749.3T patent/LT2331118T/lt unknown
- 2009-10-01 US US12/571,776 patent/US8119139B2/en active Active
- 2009-10-01 US US12/571,602 patent/US8318677B2/en active Active
2012
- 2012-01-09 US US13/346,598 patent/US8961985B2/en active Active
- 2012-08-17 US US13/588,206 patent/US8653035B2/en active Active
2013
- 2013-03-15 US US13/841,013 patent/US8895514B2/en active Active
2014
- 2014-06-19 JP JP2014126001A patent/JP5883476B2/ja not_active Expired - Fee Related
- 2014-12-05 US US14/562,156 patent/US10227381B2/en active Active
2015
- 2015-02-12 CY CY20151100139T patent/CY1116302T1/el unknown
- 2015-02-26 HR HRP20150223TT patent/HRP20150223T8/hr unknown
- 2015-10-08 JP JP2015200021A patent/JP6150859B2/ja not_active Expired - Fee Related
2016
- 2016-02-05 JP JP2016021002A patent/JP6214066B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136515A patent/JP6367266B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136516A patent/JP2017029135A/ja active Pending
- 2016-07-11 JP JP2016136518A patent/JP6294914B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136517A patent/JP6294913B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136519A patent/JP6297632B2/ja not_active Expired - Fee Related
- 2016-08-02 US US15/226,081 patent/US10046037B2/en active Active
- 2016-08-02 US US15/226,002 patent/US10047123B2/en active Active
- 2016-08-02 US US15/226,161 patent/US10941181B2/en not_active Expired - Fee Related
- 2016-08-02 CY CY20161100759T patent/CY1119744T1/el unknown
- 2016-08-02 US US15/226,126 patent/US10919931B2/en not_active Expired - Fee Related
- 2016-08-02 US US15/226,038 patent/US10100085B2/en active Active
- 2016-08-02 US US15/226,206 patent/US10047124B2/en active Active
- 2016-08-02 US US15/226,098 patent/US10906936B2/en not_active Expired - Fee Related
- 2016-11-15 HR HRP20161504TT patent/HRP20161504T1/hr unknown
2017
- 2017-01-26 CY CY20171100124T patent/CY1118702T1/el unknown
- 2017-06-30 US US15/638,806 patent/US9993540B2/en active Active
2018
- 2018-09-19 US US16/136,008 patent/US20190010190A1/en not_active Abandoned
- 2018-12-18 HR HRP20182151TT patent/HRP20182151T1/hr unknown
- 2018-12-28 CY CY181101403T patent/CY1121098T1/el unknown
2019
- 2019-01-31 HR HRP20190202TT patent/HRP20190202T1/hr unknown
- 2019-02-12 CY CY20191100182T patent/CY1121258T1/el unknown
2020
- 2020-01-23 HR HRP20200110TT patent/HRP20200110T1/hr unknown
- 2020-01-28 CY CY20201100073T patent/CY1122677T1/el unknown
- 2020-05-05 HR HRP20200722TT patent/HRP20200722T1/hr unknown
- 2020-05-15 CY CY20201100449T patent/CY1122913T1/el unknown
- 2020-06-19 HR HRP20200988TT patent/HRP20200988T1/hr unknown
- 2020-06-26 CY CY20201100594T patent/CY1123089T1/el unknown
- 2020-06-26 HR HRP20201015TT patent/HRP20201015T8/hr unknown
- 2020-06-30 CY CY20201100606T patent/CY1123098T1/el unknown
- 2020-07-03 CY CY20201100613T patent/CY1123113T1/el unknown
- 2020-08-06 HR HRP20201228TT patent/HRP20201228T1/hr unknown
- 2020-10-19 CY CY20201100984T patent/CY1123526T1/el unknown
2021
- 2021-04-23 US US17/238,806 patent/US12221493B2/en active Active
- 2021-04-23 US US17/238,787 patent/US12234298B2/en active Active
- 2021-04-23 US US17/238,840 patent/US11136352B2/en active Active
- 2021-07-23 US US17/384,152 patent/US11208434B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CY1119744T1 (el)	2018-06-27
EP2341927B1 (en)	2016-05-04
CA2936920A1 (en)	2010-04-08
JP6294913B2 (ja)	2018-03-14
KR102133402B1 (ko)	2020-07-14
ES2584245T3 (es)	2016-09-26
EA023013B1 (ru)	2016-04-29
HUE051030T2 (hu)	2021-01-28
US20130004456A1 (en)	2013-01-03
EP2331118A1 (en)	2011-06-15
ES2804723T3 (es)	2021-02-09
ES2607460T3 (es)	2017-03-31
US8895514B2 (en)	2014-11-25
EP3106175A1 (en)	2016-12-21
PT3111952T (pt)	2019-02-05
US11208434B2 (en)	2021-12-28
LT3120869T (lt)	2020-11-10
HRP20200110T1 (hr)	2020-05-15
JP2017000148A (ja)	2017-01-05
US8119139B2 (en)	2012-02-21
SI2331118T1 (sl)	2017-01-31
RS60386B1 (sr)	2020-07-31
HUE049367T2 (hu)	2020-09-28
RS60006B1 (sr)	2020-04-30
RS60656B1 (sr)	2020-09-30
EP3120868A1 (en)	2017-01-25
SI3132801T1 (sl)	2020-03-31
US20160376313A1 (en)	2016-12-29
PT3132801T (pt)	2020-02-04
KR20220058655A (ko)	2022-05-09
US20160376315A1 (en)	2016-12-29
HRP20161504T1 (hr)	2016-12-30
PL3106175T3 (pl)	2020-08-24
BRPI0920791B8 (pt)	2022-02-15
CA2936869C (en)	2019-08-06
TR201900809T4 (tr)	2019-02-21
PT3106175T (pt)	2020-07-01
SI3120868T1 (sl)	2020-08-31
US8653035B2 (en)	2014-02-18
CA2936924C (en)	2019-07-16
EP3132801B1 (en)	2019-10-30
PT3120870T (pt)	2020-07-01
MX2011003540A (es)	2011-06-20
AU2009300088B2 (en)	2014-09-04
EA032437B1 (ru)	2019-05-31
CA2936870C (en)	2019-11-26
ES2536465T3 (es)	2015-05-25
CY1123098T1 (el)	2021-10-29
EA023378B1 (ru)	2016-05-31
EA201100587A1 (ru)	2011-10-31
KR102392070B1 (ko)	2022-04-29
DK2172211T3 (en)	2015-02-16
KR20200085381A (ko)	2020-07-14
US9993540B2 (en)	2018-06-12
HRP20200988T1 (hr)	2020-10-16
DK2331118T5 (en)	2017-06-19
ES2802226T3 (es)	2021-01-18
BRPI0920791B1 (pt)	2022-01-18
HRP20190202T1 (hr)	2019-03-22
SI2341927T1 (sl)	2016-08-31
UA125277C2 (uk)	2022-02-16
HUE050428T2 (hu)	2020-12-28
EP2172211A1 (en)	2010-04-07
RS60338B1 (sr)	2020-07-31
US12234298B2 (en)	2025-02-25
ES2612466T3 (es)	2017-05-17
LT3069728T (lt)	2019-02-11
JP2016145210A (ja)	2016-08-12
KR20180088494A (ko)	2018-08-03
US20210253637A1 (en)	2021-08-19
CA2936868A1 (en)	2010-04-08
JP2012504393A (ja)	2012-02-23
EP3111952A1 (en)	2017-01-04
US8318677B2 (en)	2012-11-27
EP3120870B1 (en)	2020-04-01
RS60385B1 (sr)	2020-07-31
HRP20201015T1 (hr)	2020-10-16
HUE031030T2 (en)	2017-06-28
PL2172211T3 (pl)	2015-05-29
HUE047365T2 (hu)	2020-04-28
DK3132801T3 (da)	2020-02-10
PL3124043T3 (pl)	2020-07-27
HUE049366T2 (hu)	2020-09-28
SI3106175T1 (sl)	2020-08-31
CA2936982A1 (en)	2010-04-08
NZ603016A (en)	2014-05-30
EP3124043B1 (en)	2020-04-29
RS53782B1 (sr)	2015-06-30
WO2010037513A1 (en)	2010-04-08
JP5883476B2 (ja)	2016-03-15
EP3120869A1 (en)	2017-01-25
HRP20150223T1 (hr)	2015-06-05
ES2788129T8 (es)	2020-11-04
CA2936887A1 (en)	2010-04-08
RS58229B1 (sr)	2019-03-29
CA2936870A1 (en)	2010-04-08
KR20160103558A (ko)	2016-09-01
US20160376314A1 (en)	2016-12-29
US8961985B2 (en)	2015-02-24
EP2172212A3 (en)	2010-04-14
HRP20150223T8 (hr)	2015-07-03
US10047123B2 (en)	2018-08-14
CN102170901B (zh)	2015-01-07
JP6367266B2 (ja)	2018-08-01
EP3111952B1 (en)	2018-10-31
CA2936869A1 (en)	2010-04-08
CA2936924A1 (en)	2010-04-08
CY1116302T1 (el)	2017-02-08
PT2172212T (pt)	2016-12-22
EP3106175B1 (en)	2020-04-01
PT3120869T (pt)	2020-09-22
US20160376317A1 (en)	2016-12-29
JP2017029135A (ja)	2017-02-09
DK2331118T3 (da)	2017-01-09
CA2936887C (en)	2019-11-12
JP6214066B2 (ja)	2017-10-18
EP3120870A1 (en)	2017-01-25
US20150125478A1 (en)	2015-05-07
NZ624533A (en)	2015-09-25
SI2172212T1 (sl)	2016-12-30
NZ591882A (en)	2012-12-21
PL2331118T3 (pl)	2017-05-31
US10941181B2 (en)	2021-03-09
HRP20200722T1 (hr)	2020-10-16
CA2936868C (en)	2019-10-22
UA103202C2 (ru)	2013-09-25
US20170326217A1 (en)	2017-11-16
US10919931B2 (en)	2021-02-16
HRP20201025T8 (hr)	2022-01-07
US20160376316A1 (en)	2016-12-29
PT3124043T (pt)	2020-05-12
JP2017018102A (ja)	2017-01-26
LT3124043T (lt)	2020-07-10
US20160376312A1 (en)	2016-12-29
SI3120870T1 (sl)	2020-08-31
PL2341927T3 (pl)	2016-11-30
PL3120870T3 (pl)	2020-07-27
RS55043B1 (sr)	2016-12-30
PL2172212T3 (pl)	2017-04-28
EP2172212A2 (en)	2010-04-07
KR20110074894A (ko)	2011-07-04
RS60381B1 (sr)	2020-07-31
CA2936920C (en)	2019-12-03
PL3111952T3 (pl)	2019-04-30
US12221493B2 (en)	2025-02-11
CA2739384A1 (en)	2010-04-08
RS55531B1 (sr)	2017-05-31
PL3120868T3 (pl)	2020-08-24
EP3124043A1 (en)	2017-02-01
JP5855940B2 (ja)	2016-02-09
JP2012504563A (ja)	2012-02-23
US20210238227A1 (en)	2021-08-05
DK3124043T3 (da)	2020-05-04
DK2341927T3 (en)	2016-08-15
DK3111952T3 (en)	2019-01-28
US11136352B2 (en)	2021-10-05
DK3120870T3 (da)	2020-06-22
US10227381B2 (en)	2019-03-12
JP2017023136A (ja)	2017-02-02
PT3069728T (pt)	2019-02-13
US10047124B2 (en)	2018-08-14
LT3120868T (lt)	2020-08-10
MX338294B (es)	2016-04-11
CA2739387C (en)	2019-10-29
EP3120869B1 (en)	2020-07-22
HUE030296T2 (en)	2017-04-28
JP2017018101A (ja)	2017-01-26
DK3120869T3 (da)	2020-08-10
US20190010190A1 (en)	2019-01-10
CY1123113T1 (el)	2021-10-29
HUE041446T2 (hu)	2019-05-28
US10906936B2 (en)	2021-02-02
LT3132801T (lt)	2020-02-10
NZ591855A (en)	2012-11-30
US20210261614A1 (en)	2021-08-26
TR201900852T4 (tr)	2019-02-21
SI3124043T1 (sl)	2020-07-31
EP2172212B1 (en)	2016-10-05
CA2739387A1 (en)	2010-04-08
CY1118702T1 (el)	2017-07-12
ES2710608T3 (es)	2019-04-26
JP6297632B2 (ja)	2018-03-20
CY1121258T1 (el)	2020-05-29
EP3132801A1 (en)	2017-02-22
HRP20201228T1 (hr)	2021-02-05
EP3120868B1 (en)	2020-04-08
HK1159526A1 (zh)	2012-08-03
ES2819244T3 (es)	2021-04-15
ES2802227T3 (es)	2021-01-18
LT3111952T (lt)	2018-12-27
CY1123089T1 (el)	2021-10-29
HRP20201015T8 (hr)	2022-01-21
AU2009300087A1 (en)	2010-04-08
PL3069728T3 (pl)	2019-05-31
PL3120869T3 (pl)	2021-01-25
JP5753783B2 (ja)	2015-07-22
ES2788129T3 (es)	2020-10-20
HRP20201025T1 (hr)	2020-12-25
HUE042115T2 (hu)	2019-06-28
LT2331118T (lt)	2016-12-27
CY1123526T1 (el)	2022-03-24
US20130309193A1 (en)	2013-11-21
JP2016047825A (ja)	2016-04-07
MX2011003539A (es)	2011-06-20
RS58443B1 (sr)	2019-04-30
JP6150859B2 (ja)	2017-06-21
ES2770090T3 (es)	2020-06-30
PT2331118T (pt)	2017-02-06
US20210347822A1 (en)	2021-11-11
PT2341927T (pt)	2016-08-02
KR101687840B1 (ko)	2016-12-19
CY1121098T1 (el)	2019-12-11
HRP20170115T1 (hr)	2017-03-24
HUE029360T2 (en)	2017-02-28
UA110599C2 (uk)	2016-01-25
DK2172212T3 (da)	2016-12-19
EP2341927A2 (en)	2011-07-13
WO2010037514A2 (en)	2010-04-08
CA2739384C (en)	2017-05-02
EP2172211B1 (en)	2014-12-03
CN102170901A (zh)	2011-08-31
US20120141517A1 (en)	2012-06-07
US20100158931A1 (en)	2010-06-24
CA2936982C (en)	2019-12-03
KR101883426B1 (ko)	2018-07-31
KR101756488B1 (ko)	2017-07-11
EP3069728A1 (en)	2016-09-21
US10100085B2 (en)	2018-10-16
US20110002963A1 (en)	2011-01-06
KR20110082155A (ko)	2011-07-18
EP3069728B1 (en)	2018-11-14
HK1161106A1 (en)	2012-08-24
EA201100586A1 (ru)	2011-10-31
CY1122677T1 (el)	2021-03-12
EP2331118B1 (en)	2016-10-26
CN106986919A (zh)	2017-07-28
AU2009300087B2 (en)	2014-09-04
SI3069728T1 (sl)	2019-03-29
LT3106175T (lt)	2020-08-10
SI3111952T1 (sl)	2019-01-31
DK3120868T3 (da)	2020-06-22
BRPI0920759A2 (pt)	2016-03-08
AU2009300088A1 (en)	2010-04-08
DK3069728T3 (en)	2019-02-25
SI3120869T1 (sl)	2020-10-30
ES2708654T3 (es)	2019-04-10
JP6294914B2 (ja)	2018-03-14
PT2172211E (pt)	2015-03-09
LT3120870T (lt)	2020-08-10
SI2172211T1 (sl)	2015-03-31
DK3106175T3 (da)	2020-06-22
RS55543B1 (sr)	2017-05-31
CY1122913T1 (el)	2021-10-29
US20160355550A1 (en)	2016-12-08
CN102170900A (zh)	2011-08-31
JP2014239681A (ja)	2014-12-25
EA201401104A1 (ru)	2015-05-29
HRP20182151T1 (hr)	2019-02-08
HUE049364T2 (hu)	2020-09-28
WO2010037514A3 (en)	2010-06-03
PT3120868T (pt)	2020-07-16
PL3132801T3 (pl)	2020-06-15
BRPI0920791A2 (pt)	2019-12-10
HRP20160915T1 (hr)	2016-10-07
US10046037B2 (en)	2018-08-14
CN102170900B (zh)	2016-10-26

Publication	Publication Date	Title
HRP20190202T1 (hr)	2019-03-22	Nova imunoterapija protiv nekoliko tumora uključujući tumore živčanih stanica i tumore mozga
DK2183361T3 (en)	2015-07-27	Novel immunotherapy against brain tumors
PL2245037T3 (pl)	2015-01-30	Nowe związki i sposoby leczenia
GB0819280D0 (en)	2008-11-26	Imgaing and radiotherapy methods
PL2105501T3 (pl)	2016-03-31	Innowacyjna immunoterapia przeciwko nowotworom neuronów i mózgu
CA3244417A1 (en)	2025-10-30	Brain stimulation